Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 20/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 8/20 | 0.74 |
| ▸ | PRKCG | P05129 | 8/20 | 0.74 |
| ▸ | PRKCB | P05771 | 8/20 | 0.74 |
| ▸ | PRKCA | P17252 | 8/20 | 0.74 |
| ▸ | PRKCH | P24723 | 8/20 | 0.74 |
| ▸ | PRKCI | P41743 | 8/20 | 0.74 |
| ▸ | PRKCE | Q02156 | 8/20 | 0.74 |
| ▸ | PRKCQ | Q04759 | 8/20 | 0.74 |
| ▸ | PRKCZ | Q05513 | 8/20 | 0.74 |
| ▸ | PRKCD | Q05655 | 8/20 | 0.74 |
| ▸ | PRKD1 | Q15139 | 8/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14422834 | 0.91 | TOP1 (0.84) | TOP1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL14581742 | 0.90 | TOP1 (0.81) | TOP1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL8500729 | 0.90 | TOP1 (0.81) | TOP1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL29489888 | 0.90 | TOP1 (0.87) | TOP1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL6739046 | 0.90 | TOP1 (0.87) | TOP1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL3969257 | 0.88 | TOP1 (1.00) | TOP1PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL14581767 | 0.85 | TOP1 (0.76) | TOP1PRKD3PRKCGPRKCBPRKCA | |
| Edotecarin SCHEMBL14422833 | 0.85 | TOP1 (1.00) | TOP1PRKD3PRKCGPRKCBPRKCA | |
| Edotecarin SCHEMBL29358386 | 0.85 | TOP1 (1.00) | TOP1PRKD3PRKCGPRKCBPRKCA | |
| Edotecarin SCHEMBL29358250 | 0.85 | TOP1 (1.00) | TOP1PRKD3PRKCGPRKCBPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-12-05 | — | — | US | disclosed |
| WO-2022204184-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| US-5668271-A | Indolopyrrolocarbazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1997-09-16 | — | — | US | disclosed |
| US-5591842-A | ANTICARCINOGENIC AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1997-01-07 | — | — | US | disclosed |
| US-5589365-A | ANTITUMOR | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1996-12-31 | — | — | US | disclosed |
| EP-0545195-B1 | Indolopyrrolocarbazole derivatives | BANYU PHARMA CO LTD (JP) | 1995-11-22 | — | — | EP | disclosed |
| EP-0545195-A1 | Indolopyrrolocarbazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | TOP1 531/4885PRKD3 1398/4885PRKCG 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.